Strategies for improving the management of immune-related adverse events
With the advent of immunotherapeutic agents, durable and dramatic responses have been observed in several hard-to-treat malignancies, outlining a roadmap to conquering cancer. Immune checkpoint inhibitors (ICPi) are a class of immunotherapeutic agents that attack the tumor cells by reinvigorating th...
Saved in:
| Main Authors: | James L Gulley, Patrick Hwu, Gennaro Ciliberto, Aung Naing, Funda Meric-Bernstam, Michael B Atkins, Joud Hajjar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001754.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors
by: Jonathan L Curry, et al.
Published: (2025-08-01) -
T-cell agonists in cancer immunotherapy
by: Gennaro Ciliberto, et al.
Published: (2020-10-01) -
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
by: Solange Peters, et al.
Published: (2020-05-01) -
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors
by: Lauren A Dalvin, et al.
Published: (2025-04-01) -
Immune Checkpoint Inhibitor-Related Sjögren’s Syndrome: An Ocular Immune-Related Adverse Event
by: Hideki Fukuoka, et al.
Published: (2025-05-01)